Efficacy and safety of atropine to control childhood myopia progression

Abstract

Introduction: Nearsightedness is one of the most common eye defects in people all over the world. If left untreated, it leads to a number of serious eye complications that can result in irreversible loss of vision. It is estimated that by 2050. Half of humanity will be burdened with this disadvantage, so it has become a priority to try to find ways to prevent and treat myopia, among which the administration of atropine drops is very effective.
 Aim of the study: The aim of this study is to evaluate the safety and efficacy of atropine in controlling the progression of myopia and to investigate the relationship between the dose of atropine and the effectiveness of controlling the progression of myopia.
 Material and methods: The PubMed and Google Scholar databases were used to review the literature.
 Results: Eye drops with 1% atropine showed the greatest efficacy in the control of myopia. However, their use was limited due to the occurrence of side effects such as impaired accommodation and photophobia. In the ATOM 2 study, which investigated the use of atropine in a variety of concentrations, it was found that 0.01% is the optimal concentration with good efficacy and minimal side effects. One of the breakthroughs was the LAMP study using atropine at a concentration of 0.05%, 0.025%, 0.01% in eye drops. This study provided evidence for the first time that low-concentration atropine is effective compared with placebo in myopia. In addition, both efficacy and side effects followed a concentration-dependent response ranging from 0.01% to 0.05% of atropine. Among them, 0.05% of atropine was the optimal concentration to achieve the best efficacy and safety profile.
 Conclusion: Low concentration of atropine is effective in the control of myopia. Its widespread use can help prevent the progression of myopia. However, further investigation of the rebound phenomenon and a long term, individualized approach to treatment are warranted.